Following ASCO 2026, one message is clear: innovation in oncology is accelerating and the complexity of bringing these therapies to market is evolving just as quickly.
In a recent Q&A with Pharmaceutical Executive, Anne Marie Robertson, EVP of Oncology Commercialization at EVERSANA, shares key takeaways from this year’s meeting, from breakthroughs in precision medicine to the growing importance of agility in commercialization strategy.
Breakthrough Science Is Redefining Possibility in Hard-to-Treat Cancers
This year’s ASCO highlighted meaningful progress in historically difficult-to-treat cancers by targeting previously “undruggable” mutations.
Targeting KRAS Mutations in Pancreatic Cancer
Data presented on emerging therapies signals a massive shift in standards of care. Most notably, the Phase 3 RASolute 302 trial showed that daraxonrasib, an oral multi-selective RAS inhibitor, effectively targets the KRAS gene, a mutation found in more than 90% of pancreatic cancers.
This once-daily pill demonstrated a 60% reduction in the risk of death compared to standard chemotherapy, nearly doubling median overall survival from 6.7 months to 13.2 months for previously treated metastatic pancreatic ductal adenocarcinoma PDAC.
Read the full Q&A in Pharmaceutical Executive
Advancing Precision Medicine in Lung Cancer
At the same time, updated data in lung cancer reinforced the promise of precision medicine, with targeted therapies continuing to deliver measurable improvements in survival outcomes based on specific biomarkers. For instance, the Phase 3 LIBRETTO-432 trial showed that adjuvant treatment with selpercatinib Retevmo reduced the risk of disease recurrence or death by 83% in patients with early-stage non-small cell lung cancer NSCLC harboring rare RET fusions.
AI Is Moving into Real-World Application in Oncology
Beyond the science, ASCO 2026 underscored a major shift in how AI is being applied across oncology. What was once experimental is now being operationalized and embedded into clinical workflows, supporting diagnosis, predicting patient response to specific therapies, and improving decision-making.
AI is no longer a differentiator; it is becoming a requirement to process complex genomic data and identify the right patients for these highly targeted therapies.
The Growing Complexity of Oncology Commercialization
As therapies become more targeted, commercialization becomes more complex. Patient identification remains a major barrier, with variability across markets in biomarker screening and diagnosis.
At the same time, new treatment modalities are introducing additional demands around care delivery, infrastructure, and patient support. This widening gap between innovation and system readiness presents both challenges and opportunities for biopharma companies.
Why Commercialization Agility Matters More Than Ever
One of the most important takeaways from ASCO is the pace of change. The window between clinical data readouts and commercialization decisions is shrinking. Pipeline developments are no longer passive milestones; they are actively reshaping treatment paradigms in real time.
Success will depend on the ability to master several core capabilities:
- Monitor Dynamically: Track the evolving pipeline and clinical readouts in real-time to anticipate market shifts.
- Align Strategy Early: Prepare commercialization, infrastructure, and diagnostic pathways well ahead of regulatory approval.
- Adapt Quickly: Pivot messaging, field team deployment, and patient support rapidly as new biomarker data emerges.
What Comes Next for Biopharma
As innovation accelerates, success in oncology will increasingly come down to agility: how quickly organizations can interpret change, adjust strategy, and bring therapies to patients efficiently. Those who invest in more integrated, flexible commercialization models will be best positioned to navigate what comes next.
Discover how to navigate these complexities with EVERSANA ONCOLOGY Commercialization™ & Cancer Drug Launch Strategies.
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…